Latest Blogs

May 16, 2017
Dr. Julia Close invites women attending the ASCO Annual Meeting to be a part of conversations about gender in medicine at the Women's Networking Center, either by joining for planned session or simply by stopping by to meet colleagues and have a cup of coffee.
May 12, 2017
Mr. Todd Pickard considers the effect of the team on professional burnout. Is your team a source of conflict and disappointment, or a source of confidence?
May 09, 2017
I take my responsibilities as a physician seriously. But when faced with my own sick child, everything on my to-do list—writing, research, even clinic—went out the window.
May 08, 2017
If you say things of consequence, there may be consequences; but the alternative is to be inconsequential. Particularly in these tumultuous times for health care and research, we need to speak up!
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!
Nov 04, 2015
I think the facet of cancer most commonly misunderstood by non-scientists (patients/families) is heterogeneity. Several presentations at the Prostate Cancer Foundation Annual Retreat touched on this theme.

Pages